Metagenomi Therapeutics Stock Forecast

Stock Price Forecast

According to 4 analysts polled by S&P Global, Metagenomi Therapeutics stock has a consensus rating of "Buy" and an average price target of $8.00. The average 1-year stock price forecast is 492.59% higher than the current stock price, while the lowest is $7.00 (+418.52%) and the highest is $9.00 (+566.67%).

Price Target: $8.00 (+492.59%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$7.00	$8.00	$8.00	$9.00
Change	+418.52%	+492.59%	+492.59%	+566.67%

Analyst Ratings

The average analyst rating for Metagenomi Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26	May '26
Strong Buy	3	3	3	3	3	2
Buy	1	1	1	1	1	1
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	4	4	4	4	4	3

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Yanan Zhu Wells Fargo	Wells Fargo	Buy Maintains $12 → $9	Buy	Maintains	$12 → $9	+566.67%	May 12, 2026
Mitchell S. Kapoor HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $7	Strong Buy	Reiterates	$7	+418.52%	Aug 19, 2025
Geulah Livshits Chardan Capital	Chardan Capital	Strong Buy Maintains $12 → $11	Strong Buy	Maintains	$12 → $11	+714.81%	Aug 15, 2025
Yanan Zhu Wells Fargo	Wells Fargo	Buy Maintains $16 → $12	Buy	Maintains	$16 → $12	+788.89%	Aug 14, 2025
Geulah Livshits Chardan Capital	Chardan Capital	Strong Buy Maintains $13 → $12	Strong Buy	Maintains	$13 → $12	+788.89%	May 15, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

15.05M

from 25.21M

-40.31%

from 25.21M

Revenue Next Year

15.43M

from 15.05M

2.52%

from 15.05M

EPS This Year

-2.22

from -2.36

EPS Next Year

-1.61

from -2.22

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	243.00K	17.20M	44.76M	52.30M	25.21M	15.05M	15.43M
Revenue Growth	-	6,978.19%	160.21%	16.85%	-51.79%	-40.31%	2.52%
EPS	-3.77	-12.82	-20.05	-2.36	-2.36	-2.22	-1.61
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	6	6

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027
High	19.6M	21.0M
Avg	15.0M	15.4M
Low	8.5M	9.8M

Revenue Growth

Revenue Growth	2026	2027
High	-22.1%	39.5%
Avg	-40.3%	2.5%
Low	-66.2%	-34.9%

EPS Forecast

EPS	2026	2027
High	-2.13	-0.96
Avg	-2.22	-1.61
Low	-2.31	-2.09

EPS Growth

EPS Growth	2026	2027
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.